Interestingly, other studies have found highly expressed TACSTD2 in aggressive endometrial carcinomas associated with tumor invasion (Bignotti et al., 2011), and it has been suggested as an attractive target for cancer immunotherapy in biologically aggressive endometrial carcinomas (Bignotti et al., 2012). This evidence concerns the gene TACSTD2 and endometrial carcinoma.